Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

This article was originally published in The Tan Sheet

Executive Summary

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.


Related Content

DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study
Five Shanghai Suspects Charged After FDA Undercover Work On Spiked Supplements
BMPEA In Supplements Spells Trouble To Researchers; FDA Has Different Idea
‘False Advertising’ Complaints Let Supplement Firms’ Insurers Off The Hook
Recall DMAA Analog While FDA Evaluates Safety – CRN, Researchers
State Enforcement Needed On Weight Loss, Bodybuilding Supplements – Study
FDA Using “All Available Tools” To Remove DMAA From Market
DMAA Supplements Banned In U.K., Hamstrung In U.S.
DMAA Warnings Shed Light On FDA NDI Enforcement
Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts